A citation-based method for searching scientific literature

J Dupre, S A Ross, D Watson, J C Brown. J Clin Endocrinol Metab 1973
Times Cited: 734







List of co-cited articles
1635 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Glucagon-like peptide-1 7-36: a physiological incretin in man.
B Kreymann, G Williams, M A Ghatei, S R Bloom. Lancet 1987
37

Inhibition of gastric inhibitory polypeptide signaling prevents obesity.
Kazumasa Miyawaki, Yuichiro Yamada, Nobuhiro Ban, Yu Ihara, Katsushi Tsukiyama, Heying Zhou, Shimpei Fujimoto, Akira Oku, Kinsuke Tsuda, Shinya Toyokuni,[...]. Nat Med 2002
641
36

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
344
29

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
331
25

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.
Mikkel Christensen, Louise Vedtofte, Jens J Holst, Tina Vilsbøll, Filip K Knop. Diabetes 2011
210
22

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
207
22

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
M Nauck, F Stöckmann, R Ebert, W Creutzfeldt. Diabetologia 1986
913
21

NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE.
N MCINTYRE, C D HOLDSWORTH, D S TURNER. Lancet 1964
573
20

Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
Lærke S Gasbjerg, Mads M Helsted, Bolette Hartmann, Mette H Jensen, Maria B N Gabe, Alexander H Sparre-Ulrich, Simon Veedfald, Signe Stensen, Amalie R Lanng, Natasha C Bergmann,[...]. Diabetes 2019
75
26

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
Elizabeth A Killion, Jinghong Wang, Junming Yie, Stone D-H Shi, Darren Bates, Xiaoshan Min, Renee Komorowski, Todd Hager, Liying Deng, Larissa Atangan,[...]. Sci Transl Med 2018
92
20


Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
18

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Piotr A Mroz, Brian Finan, Vasily Gelfanov, Bin Yang, Matthias H Tschöp, Richard D DiMarchi, Diego Perez-Tilve. Mol Metab 2019
85
21

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
163
17


Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
17

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut.
J J Holst, C Orskov, O V Nielsen, T W Schwartz. FEBS Lett 1987
495
17


Incretin hormones: Their role in health and disease.
Michael A Nauck, Juris J Meier. Diabetes Obes Metab 2018
262
17

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
359
16

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.
M A Nauck, E Homberger, E G Siegel, R C Allen, R P Eaton, R Ebert, W Creutzfeldt. J Clin Endocrinol Metab 1986
597
16


PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION.
H ELRICK, L STIMMLER, C J HLAD, Y ARAI. J Clin Endocrinol Metab 1964
681
15

A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Pia K Nørregaard, Maria A Deryabina, Pernille Tofteng Shelton, Jacob U Fog, Jens R Daugaard, Per-Olof Eriksson, Lone F Larsen, Lene Jessen. Diabetes Obes Metab 2018
58
25

GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis.
Su-Jin Kim, Cuilan Nian, Subashini Karunakaran, Susanne M Clee, Carlos M Isales, Christopher H S McIntosh. PLoS One 2012
101
15


Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
A Flint, A Raben, A Astrup, J J Holst. J Clin Invest 1998
962
15


The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor.
Meena Asmar, Ali Asmar, Lene Simonsen, Lærke Smidt Gasbjerg, Alexander Hovard Sparre-Ulrich, Mette Marie Rosenkilde, Bolette Hartmann, Flemming Dela, Jens Juul Holst, Jens Bülow. Diabetes 2017
66
21

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
14

Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
Alice E Adriaenssens, Emma K Biggs, Tamana Darwish, John Tadross, Tanmay Sukthankar, Milind Girish, Joseph Polex-Wolf, Brain Y Lam, Ilona Zvetkova, Warren Pan,[...]. Cell Metab 2019
93
15


Reappraisal of GIP Pharmacology for Metabolic Diseases.
Brian Finan, Timo D Müller, Christoffer Clemmensen, Diego Perez-Tilve, Richard D DiMarchi, Matthias H Tschöp. Trends Mol Med 2016
101
13

GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study.
Lærke S Gasbjerg, Mikkel B Christensen, Bolette Hartmann, Amalie R Lanng, Alexander H Sparre-Ulrich, Maria B N Gabe, Flemming Dela, Tina Vilsbøll, Jens J Holst, Mette M Rosenkilde,[...]. Diabetologia 2018
52
25

Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.
Anne Nissen, Mikkel Christensen, Filip K Knop, Tina Vilsbøll, Jens J Holst, Bolette Hartmann. J Clin Endocrinol Metab 2014
78
16

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.
Jonathan W Day, Nickki Ottaway, James T Patterson, Vasily Gelfanov, David Smiley, Jas Gidda, Hannes Findeisen, Dennis Bruemmer, Daniel J Drucker, Nilika Chaudhary,[...]. Nat Chem Biol 2009
390
13

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
13

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
842
13


Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia.
J J Meier, B Gallwitz, N Siepmann, J J Holst, C F Deacon, W E Schmidt, M A Nauck. Diabetologia 2003
224
12

N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor.
L S Hansen, A H Sparre-Ulrich, M Christensen, F K Knop, B Hartmann, J J Holst, M M Rosenkilde. Br J Pharmacol 2016
56
21


Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man.
R Eissele, R Göke, S Willemer, H P Harthus, H Vermeer, R Arnold, B Göke. Eur J Clin Invest 1992
465
12

A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
12

Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Alessandro Pocai, Paul E Carrington, Jennifer R Adams, Michael Wright, George Eiermann, Lan Zhu, Xiaobing Du, Aleksandr Petrov, Michael E Lassman, Guoqiang Jiang,[...]. Diabetes 2009
276
12


Insulin Secretion Depends on Intra-islet Glucagon Signaling.
Berit Svendsen, Olav Larsen, Maria Buur Nordskov Gabe, Charlotte Bayer Christiansen, Mette M Rosenkilde, Daniel J Drucker, Jens Juul Holst. Cell Rep 2018
155
12

Preparation of highly active enterogastrone.
J C Brown, R A Pederson, E Jorpes, V Mutt. Can J Physiol Pharmacol 1969
101
11

GIP(3-30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release.
A H Sparre-Ulrich, M N Gabe, L S Gasbjerg, C B Christiansen, B Svendsen, B Hartmann, J J Holst, M M Rosenkilde. Biochem Pharmacol 2017
44
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.